Unique biodiversity creating opportunities
DEINOVE is one of the only biotech companies to own such a wide biodiversity, thus gaining potential access to many biobased compounds, some of them absolutely original and extracted from rare bacteria, namely Deinococcus strains. DEINOVE taps into its biological resources in the search of new compounds and optimizes the production of selected strains to reach the adequate performance.
Discovered by chance in 1956 by biologist Arthur Anderson, the Deinococcus bacterium has exceptional properties that had never been used industrially before DEINOVE:
- The ability to integrate and sustainably preserve large fragments of exogenous DNA in its genome;
- Original enzymatic and metabolic properties: the ability to produce rare compounds (natural carotenoids, enzymes, antibiotics, antifungals, etc.) from various plant sugars that other commonly used organisms are unable to use (such as certain complex sugars), but also the ability to simultaneously assimilate several types of sugars.
Mattimore V, Battista JR. Radioresistance of Deinococcus radiodurans: functions necessary to survive ionizing radiation are also necessary to survive prolonged desiccation J Bacteriol. (1996) Feb;178(3):633-7
A state-of-the-art technological platform for selecting and developing molecules of value to the healthcare, nutrition and cosmetics markets
DEINOVE has built a highly sophisticated platform for screening and integrated genetic, metabolic and fermentation engineering of strains. With this platform, the teams screen the strain library looking for bacteria that produce innovative compounds, optimize the research molecule’s level of production before culturing it for the effective production of the target compound. Once proof of concept has been established in the laboratory, the candidate strain is then tested in pilot fermenters to optimize the culture conditions and to prepare for ramping up to industrial production.